Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2022Liver CancerOpen Access

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

Masatoshi Kudo
Masatoshi KudoKanazawa University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Masatoshi Kudo (2022) studied this question.

synapsesocial.com/papers/69dd665780eea7d3f699c769https://doi.org/10.1159/000526163
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identification of α‐fetoprotein‐derived peptides recognized by cytotoxic T lymphocytes in HLA‐A24+ patients with hepatocellular carcinoma2005 · 73 citations
  2. 2Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology2021 · 1,799 citations
  3. 3Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis2020 · 48 citations
  4. 4Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Predicts Tumor Differentiation, P-glycoprotein Expression, and Outcome after Resection in Hepatocellular Carcinoma2007 · 191 citations
  5. 5Identification of Keratin 19–Positive Cancer Stem Cells Associating Human Hepatocellular Carcinoma Using 18F-Fluorodeoxyglucose Positron Emission Tomography2016 · 31 citations